Monoclonal Antibody RSV Prevention for newborns and infants
Protect Your Little One from RSV with Monoclonal Antibody RSV Prevention for newborns and infants
Effectiveness of Monoclonal Antibody for RSV Prevention (Nirsevimab) in Infants:
- Reduces the risk of RSV infection by up to 79.5%
- Lowers the risk of hospitalization due to lower respiratory tract infection from RSV by up to 83.2%
- Decreases ICU ventilator use by 75.3%
- Provides protection for up to 5 months, covering the peak RSV season
Contraindications for Monoclonal Antibody for RSV Prevention (Nirsevimab)
Do not administer the monoclonal antibody for RSV prevention to children with a history of severe allergic reactions to Nirsevimab or its components, such as arginine or histidine.
Additional Notes:
- Monoclonal antibody for RSV prevention is important for building immunity in infants during their first year of life
- Infants aged 0–2 years with underlying health conditions are eligible to receive the injection
- It can be administered alongside routine childhood vaccines without the need to space them out—even with live vaccines, as it does not interfere with vaccine-induced immunity.
- Monoclonal antibody for RSV prevention can be given at the same time as other vaccines, as long as each is injected at a different site.
Program
Monoclonal Antibody for RSV Prevention (Nirsevimab) – 1 Dose (50 mg)
24,100 Baht .
(for newborn aged 0-1 month and weight under 5 kg)
Monoclonal Antibody for RSV Prevention (Nirsevimab) – 1 Dose (100 mg)
24,100 Baht .
(for infants aged over 1 month -12 months and weigh over 5 kg)
Monoclonal Antibody for RSV Prevention (Nirsevimab) – 2 Doses (200 mg)
48,200 Baht .
for children aged 12–24 months
Terms and Conditions:
- Prices do not include doctor’s fees or hospital service fees
Services available at
- Samitivej International Children’s Hospital (Srinakarin), 3rd Floor Samitivej International Children’s Hospital (Sukhumvit), 2nd Floor
- Today – September 30, 2026
